Beyond Your Cancer

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Patients Treated

The introduction of Cesium-131 represents the culmination of decades of work and millions of dollars of investment. Top medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.

The word brachytherapy derives from the Greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland.

Treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. Pioneers in brachytherapy research initially theorized about the use of Cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and Iodine-125 emerged as an alternative.

Beginning in 1967, Iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. While its use continues to this day, many patients and doctors in recent years have chosen Palladium-103, a faster-acting, shorter half-life isotope than Iodine-125. In order to obtain the clinical benefits of Palladium’s short half-life, patients and clinicians were forced to settle for lower energy or tissue penetrating power.

A team of scientists continued to believe the physical characteristics of Cesium-131* could potentially provide superior clinical benefits for seed brachytherapy patients. The team developed the patented process for economically separating and purifying Cesium-131 and in 1998 Isoray was founded to manufacture and commercialize Cesium-131 brachytherapy seeds to treat cancers.

Investors

Review our SEC Filings, Codes of Conduct, & Management Teams.

Learn More

Careers

We are always looking for talented people to join our team.

Learn More

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests...
Read More

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the...
Read More

Did Beau Biden’s Battle with Brain Cancer Change the Course of History?

Change in healthcare can be agonizingly slow. The scientific rigors and huge financial investments needed to bring novel life saving therapies help...
Read More

Bringing Compassion and Hope to Cancer Patients

The following article originally appeared in the Winter/Spring 2017 MicroCap Review Magazine. A small company in Richland, WA is dedicated to making...
Read More

Why we are looking forward to SGO 2017: Breakthroughs in treating gynecologic cancer including Cesium-131 Permanent Interstitial Brachytherapy (PIB)

Isoray is excited to be supporting the upcoming Society of Gynecologic Oncology (SGO) annual meeting, which will be held March 12-15 in National...
Read More

Join Us at the Following Events

ABS

American Brachytherapy Society

2017 ABS Annual Meeting
April 20-22, 2017
Boston, MA

AANS

American Association of Neurological Surgeons

April 22 – 26, 2017
Los Angeles, CA

AUA

American Urologic Association Annual Meeting 2017

May 12- 16, 2017
Boston, MA

AAPM

American Association of Physicists in Medicine

July 31 – August 3, 2017
Denver, CO

ASTRO

American Society for Therapeutic Radiation Oncology

September 24 – 27, 2017
San Diego Convention Center
San Diego, CA

Recent News

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the...

Women’s Cancer and Cesium-131 Treatments

Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy RICHLAND, Wash., July 6, 2016 /PRNewswire/ — IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy...

IsoRay Appoints Thomas LaVoy as CEO

Richland, WA January 14, 2016 – IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the...